Egrifta (Tesamorelin) and Exercise: What You Need to Know
HealthRX.com
The label is silent on exercise; no trial has tested it yet
From the public record
Muscle, tendon and exertion terms in FDA adverse event reports for tesamorelin
Of 2,771 adverse event reports FDA had received for tesamorelin through 2026-10-28, 190 (6.9%) name at least one muscle, tendon or exertion term. The terms named most often are myalgia (89), muscle spasms (43) and musculoskeletal stiffness (33). Across every medicine in the database the same terms appear in 3.2% of reports.
| Measure | Value | Note |
|---|---|---|
| Reports naming at least one muscle, tendon or exertion term | 190 | |
| Share of all reports for tesamorelin | 6.9% | of 2,771 reports |
| Same terms across every medicine in FAERS | 3.2% | share of all reports in the database, for context |
| Myalgia | 89 reports | |
| Muscle spasms | 43 reports | |
| Musculoskeletal stiffness | 33 reports | |
| Muscle tightness | 14 reports | |
| Muscular weakness | 13 reports |
How this was calculated
Counted FAERS reports for this medicine that name any of 21 reaction terms about muscle, tendon and exertion, then each term on its own. A report can name several terms. Reports are unverified and do not show cause.
Reports with tesamorelin as a single-ingredient active substance (any brand) naming any of 21 MedDRA muscle, tendon or exertion terms, all years to 2026-10-28
At a glance
- Approved use / excess abdominal fat in HIV-infected adults with lipodystrophy [1]
- Exercise in the label / no restriction stated; workout timing not addressed [1][2]
- Drug-plus-exercise trial / TRIUMPH, 100 sedentary adults aged 50 to 80, 24 weeks plus a 24-week extension; protocol published, results not reported [3]
- Egrifta SV dose / 1.4 mg subcutaneously into the abdomen once daily [1]
- Visceral fat change at week 26, pooled trials / -24 cm2 with tesamorelin vs +2 cm2 with placebo [5]
- After a switch to placebo / visceral fat change of +16% to +22% from week 26 to week 52, versus 0% to -5% in those who continued [1]
- Glucose / HbA1c of 6.5% or higher in 5% on tesamorelin vs 1% on placebo by week 26 [1]
- Competitive sport / named by WADA and prohibited at all times [6]
Does the Egrifta label say anything about exercise?
The Egrifta SV and Egrifta WR prescribing information do not address exercise, physical activity or workout timing [1][2]. What the labels do specify is how the drug is given: 1.4 mg subcutaneously once daily for Egrifta SV and 1.28 mg once daily for Egrifta WR, injected into the abdomen with rotating sites [1][2]. The Egrifta SV label says not to inject into scar tissue, bruises or the navel [1]. The two formulations are not substitutable [2].
The drug interaction section is short and covers glucocorticoid replacement and medicines cleared by CYP450 enzymes, with corticosteroids, sex steroids, anticonvulsants and cyclosporine named as examples [1]. Exercise is not part of it.
What tesamorelin does, in plain terms
Tesamorelin is a synthetic analog of growth hormone-releasing factor. It binds GRF receptors on pituitary somatotroph cells and stimulates release of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [1]. The label describes that growth hormone as both anabolic and lipolytic [1]. Tesamorelin is a peptide, not growth hormone, and it is approved only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy; the label states it is not indicated for weight loss and has a weight-neutral effect [1].
Because tesamorelin raises GH and IGF-1, the label warns about glucose intolerance or diabetes, fluid retention, elevated IGF-1 and neoplasms [1].
Is there a study of tesamorelin plus exercise?
TRIUMPH (registered as NCT06554717) is a double-blind, two-site randomized trial protocol. It is designed for 100 sedentary adults aged 50 to 80 living with HIV who are frail or at risk of frailty and who have excess abdominal adiposity. Participants are assigned to tesamorelin or placebo as an adjunct to a home-based, semisupervised exercise program for 24 weeks, followed by 24 weeks of independent exercise. The trial is set up to measure physical function, muscle content and quality, quality of life and exercise adherence at weeks 24 and 48, plus muscle fat and mitochondrial function at week 24 [3]. The paper describing it is a trial protocol; it reports no outcomes [3].
What a small trial found about muscle recovery after exercise
A smaller study looked at muscle energetics rather than a training program. Thirty-nine obese men and women with reduced GH secretion were randomized to tesamorelin or placebo for 12 months, and phosphocreatine recovery after submaximal exercise was measured by phosphorus-31 magnetic resonance spectroscopy at baseline and at 12 months. Tesamorelin raised IGF-1 more than placebo (a change of 102.9 ± 31.8 μg/L versus 22.8 ± 8.9 μg/L, P=.02), and the rise in IGF-1 correlated with improvement in phosphocreatine recovery (R=0.56 across the group; R=0.71 among those on tesamorelin) [4].
The authors describe the finding as suggestive of improved mitochondrial function. Phosphocreatine recovery is not a measure of strength, endurance or workout performance, and the participants were obese adults with reduced GH secretion, the population studied rather than the labeled one [4].
What tesamorelin does to visceral fat, and what happens when it stops
Pooling the two phase 3 trials (806 patients: 543 on tesamorelin, 263 on placebo), visceral fat fell by 24 cm2 at week 26 on tesamorelin and rose by 2 cm2 on placebo, a treatment effect of -15.4%; triglycerides fell 37 mg/dL versus a 6 mg/dL rise [5]. In the larger trial alone (412 patients), visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo, with triglycerides down 50 mg/dL versus up 9 mg/dL [7].
The effect does not hold after the drug stops. In the extension phases, people who had received tesamorelin and were switched to placebo regained visceral fat, with a change of +16% to +22% from week 26 to week 52, while those who stayed on tesamorelin had a change of 0% to -5% [1].
Labeled effects to be aware of during training
Joint pain, swelling and edema. Fluid retention is a labeled warning and may include edema, arthralgia and carpal tunnel syndrome [1]. In the adverse reaction table, arthralgia occurred in 13% on tesamorelin versus 11% on placebo, peripheral edema 6% versus 2%, myalgia 6% versus 2%, and carpal tunnel syndrome 1% versus 0% [1].
Injection sites. Injection site reactions occurred in 25% of tesamorelin patients and 14% of placebo patients during the first 26 weeks [1].
Allergic reactions. Hypersensitivity reactions occurred in 4% of tesamorelin-treated patients and included itching, redness, flushing, hives and rash; the label says to discontinue treatment and seek prompt medical attention if a reaction is suspected [1].
Glucose. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of 3.3 (95% CI 1.4 to 9.6) [1]. The label says to evaluate glucose status before starting, monitor periodically during treatment, and consider discontinuing in patients who develop glucose intolerance and do not show a clear efficacy response [1]. The phase 3 trials excluded people with type 1 or type 2 diabetes and anyone previously treated with insulin or oral glucose-lowering drugs [1].
IGF-1. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; at 52 weeks, 34% and 23% [1]. The label says to monitor IGF-1 and consider discontinuing with persistent elevations, for example above 3 SDS, particularly if the efficacy response is not robust [1].
Questions worth asking
Is tesamorelin allowed in competitive sport?
No. WADA's Prohibited List names tesamorelin in section S2.2.4 among growth hormone releasing factors, and it is prohibited at all times, in and out of competition. It appears on the 2026 List and remains on the 2027 List, and S2 substances are non-Specified Substances [6][8].
What is not known
The studies described above do not establish whether exercise adds to tesamorelin's visceral fat reduction in people with HIV, whether the time of injection relative to training changes anything, or whether training limits the regain after the drug is stopped. TRIUMPH's listed endpoints are physical function, muscle, quality of life and exercise adherence [3].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Can I exercise while taking Egrifta?
Does exercise make tesamorelin work better?
Should I inject before or after a workout?
Does tesamorelin affect blood sugar during exercise?
Does the visceral fat come back if I stop the drug?
Is tesamorelin banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How long does it take for tesamorelin to work?
Visceral fat was measured at week 26 in the two phase 3 trials, where it fell by 24 cm2 on tesamorelin versus a rise of 2 cm2 on placebo. The benefit did not hold after stopping: in people switched to placebo, visceral fat rose 16% to 22% from week 26 to week 52.
Does tesa peptide really work?
Tesamorelin reduced visceral fat in the phase 3 trials: it fell by 24 cm2 at week 26 on tesamorelin versus a rise of 2 cm2 on placebo. It is approved only for excess abdominal fat in HIV-infected adults with lipodystrophy, is not indicated for weight loss, and the effect does not last after the drug stops.
Does tesamorelin help with workout recovery?
Not established. A small study of 39 obese adults with reduced GH secretion found that phosphocreatine recovery after submaximal exercise improved over 12 months on tesamorelin, and the rise in IGF-1 tracked with that improvement. Phosphocreatine recovery does not measure strength, endurance or workout performance.
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Erlandson KM, Gustafson L, Johnson JE, Kulik GL, Khuu V, Chahal N, et al. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open. 2026.
- Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2014;99(1):338-43.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304.
- World Anti-Doping Agency.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.
- World Anti-Doping Agency.